Skip to content
HowShorted

G1 Therapeutics, Inc. short interest in 2021

In 2021, G1 Therapeutics, Inc.'s disclosed short interest ran from 15.85% of shares outstanding on 15 Jan 2021 to 21.18% on 31 Dec 2021, a change of +5.33 percentage points. The year's high was 21.85% on 15 Dec 2021 and its low 13.71% on 12 Feb 2021, averaging 17.75% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.40 days on 31 Dec 2021. Full history: G1 Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for G1 Therapeutics, Inc. in 2021

2021 in figures

Start of year
15.85% (15 Jan 2021)
End of year
21.18% (31 Dec 2021)
Change
+5.33 pp
High
21.85% (15 Dec 2021)
Low
13.71% (12 Feb 2021)
Average
17.75%
Highest days to cover
11.40 (31 Dec 2021)
SEC filings marked
9

Every report in 2021

G1 Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.85%5.72results (8-K)
29 Jan 202114.14%5.19
12 Feb 202113.71%3.45
26 Feb 202116.64%2.2910-K filed, results (8-K)
15 Mar 202120.13%5.28
31 Mar 202119.55%7.12
15 Apr 202118.30%7.55
30 Apr 202116.75%10.99
14 May 202115.28%6.3410-Q filed, results (8-K)
28 May 202114.94%10.46
15 Jun 202114.25%4.83
30 Jun 202113.86%5.58
15 Jul 202114.55%4.05
30 Jul 202117.36%5.77
13 Aug 202117.81%9.4910-Q filed, results (8-K)
31 Aug 202118.01%8.69
15 Sep 202117.36%10.72
30 Sep 202121.30%8.42
15 Oct 202119.94%9.20
29 Oct 202120.89%9.17
15 Nov 202121.07%9.3310-Q filed, results (8-K)
30 Nov 202121.24%10.61
15 Dec 202121.85%8.69
31 Dec 202121.18%11.40

See also: G1 Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.